Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Burixafor Hydrobromide,GM CSF,Propranolol Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Exicure Completes Enrollment for GPC-100 Phase 2 Myeloma Transplant Study
Details : GPC-100 (burixafor) is a highly selective small molecule antagonist of CXCR4, being investigated with propranolol and G-CSF in multiple myeloma patients undergoing autologous transplant.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 05, 2025
Lead Product(s) : Burixafor Hydrobromide,GM CSF,Propranolol Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Burixafor Hydrobromide,Propranolol Hydrochloride,G-CSF
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Exicure Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma
Details : GPC-100 (Burixafor HBr) is a novel small molecule CXCR4 antagonist, being investigated in patients with multiple myeloma.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 14, 2025
Lead Product(s) : Burixafor Hydrobromide,Propranolol Hydrochloride,G-CSF
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Burixafor Hydrobromide,G-CSF,Propranolol Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Exicure
Deal Size : Undisclosed
Deal Type : Acquisition
Exicure Announces Purchase Agreement with GPCR Therapeutics
Details : Through the acquisition, Exicure will leverage GPCR USA pipeline, which include GPC-100 (burixafor+propranolol) with G-CSF for the treatment of Multiple Myeloma.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 22, 2025
Lead Product(s) : Burixafor Hydrobromide,G-CSF,Propranolol Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Exicure
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : GPC-100,Propranolol Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : GPCR Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Exicure Partners with GPCR Therapeutics to Fuel New Growth in Biotech
Details : The partnership aims to advance the clinical development of the company's mid-stage product GPC-201 (GPC-100+Propanalol) for treating patients suffering from Multiple Myeloma.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 26, 2024
Lead Product(s) : GPC-100,Propranolol Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : GPCR Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Propranolol Hydrochloride
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Propranolol for the Treatment of Traumatic Brain Injury
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 15, 2024
Lead Product(s) : Propranolol Hydrochloride
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Propranolol Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lupin Gets USFDA Nod for Generic Hypertension Drug
Details : Inderal-Generic (propranolol) is a β-adrenoceptors antagonist. It is now approved for the treatment of hypertension, angina pectoris, migraine, hypertrophic subaortic stenosis.
Product Name : Inderal-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 14, 2024
Lead Product(s) : Propranolol Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Propranolol Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lupin Launches Propranolol Long-Acting Capsules to Improve Heart Health in Canada
Details : Propranolol hydrochloride tablet is a synthetic beta-adrenergic receptor blocking agent, which is indicated for the treatment of the management of hypertension.
Product Name : Inderal-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 29, 2023
Lead Product(s) : Propranolol Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Propranolol Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Innovent Biologics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 07, 2023
Lead Product(s) : Propranolol Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Innovent Biologics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Propranolol Hydrochloride
Therapeutic Area : Gastroenterology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Primary Prevention of Gastric Varices Bleed
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 15, 2023
Lead Product(s) : Propranolol Hydrochloride
Therapeutic Area : Gastroenterology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Propranolol Hydrochloride
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Continuous Blood Pressure Monitoring in Healthy Participants
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 20, 2023
Lead Product(s) : Propranolol Hydrochloride
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable